OS Therapies (NYSEAMERICAN:OSTX) Shares Down 1.1% - Time to Sell?

Key Points

• OS Therapies shares fell 1.1% during trading, with the latest price at $1.81, which reflects a significant decline in trading volume compared to the average.
• Analyst ratings are mixed, with one firm maintaining a "buy" rating and a price target of $20.00, while Zacks Research downgraded the stock to "strong sell."
• The company focuses on developing treatments for osteosarcoma and has a market cap of approximately $57.29 million with a negative P/E ratio.

OS Therapies Incorporated (NYSEAMERICAN:OSTX - Get Free Report)'s stock price fell 1.1% during trading on Thursday . The company traded as low as $1.80 and last traded at $1.81. 194,266 shares traded hands during mid-day trading, a decline of 55% from the average session volume of 433,230 shares. The stock had previously closed at $1.83.

Analyst Ratings Changes

A number of research firms recently commented on OSTX. D. Boral Capital reiterated a "buy" rating and issued a $20.00 price target on shares of OS Therapies in a research note on Friday, October 10th. Zacks Research cut shares of OS Therapies from a "hold" rating to a "strong sell" rating in a report on Monday, October 13th. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $18.00.

OS Therapies Price Performance

The stock has a market cap of $57.29 million, a P/E ratio of -2.29 and a beta of -4.09. The company has a fifty day moving average of $2.12 and a 200 day moving average of $1.86.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in OSTX. Bridgeway Capital Management LLC acquired a new position in OS Therapies in the second quarter worth approximately $47,000. XTX Topco Ltd acquired a new position in OS Therapies in the second quarter worth approximately $63,000. Finally, CM Management LLC grew its position in OS Therapies by 172.6% in the first quarter. CM Management LLC now owns 300,000 shares of the company's stock worth $462,000 after buying an additional 189,956 shares during the last quarter.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.